Gemcitabine in NK/T Cell Lymphoma

Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01660568

Enrollment

Registered

2012-08-08

Start date

2012-08-31

Completion date

2013-01-31

Last updated

2013-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NK/T Cell Lymphoma

Brief summary

We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to No maximum

Healthy volunteers

Inclusion criteria

* NK/T cell lymphoma * relapse or refractory disease * gemcitabine containing treatment

Design outcomes

Primary

Measure	Time frame
Overall response rate	2012-May

Countries

South Korea

Outcome results